BPTH (Bio-Path Holdings) Ending Cash Position: $0.01 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Path Holdings Ending Cash Position?

Bio-Path Holdings BPTH -1.94% Ending Cash Position is $0.01 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Bio-Path Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.01 Mil.

Bio-Path Holdings's quarterly Ending Cash Position stayed the same from Jun. 2025 ($0.00 Mil) to Sep. 2025 ($0.00 Mil) but then increased from Sep. 2025 ($0.00 Mil) to Mar. 2026 ($0.01 Mil).

Bio-Path Holdings's annual Ending Cash Position declined from Dec. 2022 ($10.38 Mil) to Dec. 2023 ($1.05 Mil) but then increased from Dec. 2023 ($1.05 Mil) to Dec. 2024 ($1.17 Mil).

Bio-Path Holdings Ending Cash Position Related Terms

Bio-Path Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings Ending Cash Position Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.76 23.77 10.38 1.05 1.17

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 0.12 0.00 0.00 0.01

Bio-Path Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bio-Path Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.052+0.121
=1.17

Bio-Path Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-3.4694469519536E-18+0.012
=0.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.01 Mil mean?
Bio-Path Holdings (BPTH) has a Ending Cash Position of $0.01 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' Ending Cash Position too high?
Bio-Path Holdings' current Ending Cash Position is $0.01 Mil.
How does Bio-Path Holdings' Ending Cash Position compare to VBIO and HEPA?
Bio-Path Holdings' Ending Cash Position of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current Ending Cash Position is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Ending Cash Position of $0.01 Mil. The current Ending Cash Position is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Ending Cash Position is $0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.